The Role of IFN-gamma Elispot Assay in HIV Vaccine Research

Overview

Journal Nat Protoc

Specialties Biology
Pathology
Science

Date 2009 Mar 14

PMID 19282851

Citations 77

Authors

Hendrik Streeck

Nicole Frahm

Bruce D Walker

Affiliations

Soon will be listed here.

Abstract

The interferon (IFN)-gamma Elispot assay has been widely used as a general screening method for the quantification and characterization of the human immunodeficiency virus (HIV)-specific CD8+ T cell responses. However, the predictive power of this assay has been challenged due to the lack of efficacy of a recently conducted HIV vaccine phase IIb trial, despite induction of robust Elispot responses. This finding plus improvements in multiparameter flow cytometry, which has the potential advantage of simultaneously quantifying numerous parameters, raises questions regarding the future role of IFN-gamma Elispot as a gateway to moving forward with clinical trials of candidate vaccines. However, the IFN-gamma Elispot assay has been, unlike other techniques, evaluated and validated in several proficiency panels and is advantageous in cost-effectively detecting and mapping T-cell responses. Here we present a detailed protocol for a state-of-the-art 3-d IFN-gamma Elispot assay and review further advantages and disadvantages of this method for the characterization of HIV-specific CD8+ T cell responses.

Citing Articles

Enhanced Humoral and Cellular Immune Responses Elicited by Adenoviral Delivery of SARS-CoV-2 Receptor-Binding Motif Fused to Human Fc.

Lee Y, Easwaran M, Jung Y, Qian Y, Shin H Vaccines (Basel). 2024; 12(11).

PMID: 39591150 PMC: 11598816. DOI: 10.3390/vaccines12111247.

Validation of the Enzyme-Linked ImmunoSpot Analytic Method for the Detection of Human IFN-γ from Peripheral Blood Mononuclear Cells in Response to the SARS-CoV-2 Spike Protein.

Carreto-Binaghi L, Nieto-Ponce M, Palencia-Reyes A, Chavez-Dominguez R, Blancas-Zaragoza J, Franco-Mendoza P Biomolecules. 2024; 14(10).

PMID: 39456219 PMC: 11506497. DOI: 10.3390/biom14101286.

Impact of shipping temperature on cell viability and T cell responses to bacterial antigens.

Rongkard P, Dunachie S, Kronsteiner B Wellcome Open Res. 2024; 8:188.

PMID: 38903244 PMC: 11187529. DOI: 10.12688/wellcomeopenres.18822.1.

Release Assays and Potency Assays for CAR T-Cell Interventions.

Dias J, Cadinanos-Garai A, Roddie C Adv Exp Med Biol. 2023; 1420:117-137.

PMID: 37258787 DOI: 10.1007/978-3-031-30040-0_8.

Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.

Gorovits B, Azadeh M, Buchlis G, Fiscella M, Harrison T, Havert M AAPS J. 2023; 25(3):47.

PMID: 37101079 PMC: 10132926. DOI: 10.1208/s12248-023-00814-5.

References

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

Price D, Goulder P, Klenerman P, Sewell A, Easterbrook P, Troop M . Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A. 1997; 94(5):1890-5. PMC: 20013. DOI: 10.1073/pnas.94.5.1890. View

Carrington M, OBrien S . The influence of HLA genotype on AIDS. Annu Rev Med. 2003; 54:535-51. DOI: 10.1146/annurev.med.54.101601.152346. View

Bailey J, OConnell K, Yang H, Han Y, Xu J, Jilek B . Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol. 2008; 82(15):7395-410. PMC: 2493308. DOI: 10.1128/JVI.00800-08. View

Gnann Jr J, Nelson J, Oldstone M . Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol. 1987; 61(8):2639-41. PMC: 255715. DOI: 10.1128/JVI.61.8.2639-2641.1987. View

Schmitz J, Kuroda M, Santra S, Sasseville V, Simon M, Lifton M . Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999; 283(5403):857-60. DOI: 10.1126/science.283.5403.857. View

Jin X, Bauer D, Tuttleton S, Lewin S, Gettie A, Blanchard J . Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999; 189(6):991-8. PMC: 2193038. DOI: 10.1084/jem.189.6.991. View

Czerkinsky C, Nilsson L, Nygren H, OUCHTERLONY O, Tarkowski A . A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983; 65(1-2):109-21. DOI: 10.1016/0022-1759(83)90308-3. View

Horton H, Thomas E, Stucky J, Frank I, Moodie Z, Huang Y . Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007; 323(1):39-54. PMC: 2683732. DOI: 10.1016/j.jim.2007.03.002. View

10.

Schmittel A, Keilholz U, Scheibenbogen C . Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods. 1998; 210(2):167-74. DOI: 10.1016/s0022-1759(97)00184-1. View

11.

Betts M, Nason M, West S, De Rosa S, Migueles S, Abraham J . HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107(12):4781-9. PMC: 1895811. DOI: 10.1182/blood-2005-12-4818. View

12.

Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W . Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMC: 236393. DOI: 10.1128/JVI.68.7.4650-4655.1994. View

13.

Addo M, Yu X, Rathod A, Cohen D, Eldridge R, Strick D . Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003; 77(3):2081-92. PMC: 140965. DOI: 10.1128/jvi.77.3.2081-2092.2003. View

14.

Czerkinsky C, Andersson G, Ekre H, Nilsson L, Klareskog L, OUCHTERLONY O . Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods. 1988; 110(1):29-36. DOI: 10.1016/0022-1759(88)90079-8. View

15.

Sun Y, Iglesias E, Samri A, Kamkamidze G, Decoville T, Carcelain G . A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods. 2002; 272(1-2):23-34. DOI: 10.1016/s0022-1759(02)00328-9. View

16.

Bihl F, Loggi E, Chisholm 3rd J, Hewitt H, Henry L, Linde C . Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". J Transl Med. 2005; 3(1):20. PMC: 1164435. DOI: 10.1186/1479-5876-3-20. View

17.

McElrath M, De Rosa S, Moodie Z, Dubey S, Kierstead L, Janes H . HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653):1894-1905. PMC: 2774110. DOI: 10.1016/S0140-6736(08)61592-5. View

18.

Kester K, Cummings J, Ockenhouse C, Nielsen R, Hall B, Gordon D . Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2008; 26(18):2191-202. DOI: 10.1016/j.vaccine.2008.02.048. View

19.

Frahm N, Korber B, Adams C, Szinger J, Draenert R, Addo M . Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol. 2004; 78(5):2187-200. PMC: 369231. DOI: 10.1128/jvi.78.5.2187-2200.2004. View

20.

Addo M, Altfeld M, Rosenberg E, Eldridge R, Philips M, Habeeb K . The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A. 2001; 98(4):1781-6. PMC: 29334. DOI: 10.1073/pnas.98.4.1781. View